A Collaborative Model for Breakthrough Science.
Advanced Contrast Enterprises S.A. (ACE) is a pioneering biomedical technology company transforming cancer detection through next-generation non-radioactive multimodal imaging contrast agents.
A spin-off of the National Hellenic Research Foundation (NHRF), ACE combines world-class polymer science, nanotechnology, and optical physics to deliver safer, more accurate, and radiation-free diagnostic imaging solutions.
Our Mission
To enable earlier, more precise cancer diagnosis—without compromise.
ACE’s platform harnesses conjugated polymer nanoparticles (CPNs) and polymer-lipid nanoparticles (CP-LPs) capable of dual-mode imaging— combining the structural precision of photoacoustic imaging with the molecular sensitivity of fluorescence imaging. This means doctors can see both anatomy and molecular activity in real time, all without harmful radiation.
Our Partners
ACE partners with world-leading research institutions across Europe to accelerate scientific discovery and validate its technology at the highest levels.
These collaborations give ACE access to advanced imaging facilities, clinical expertise, and multidisciplinary teams—strengthening both the rigor and real-world readiness of its platform.
